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Biomarkers for site-specific response to neoadjuvant
chemotherapy in epithelial ovarian cancer: relating MRI
changes to tumour cell load and necrosis
Jessica M. Winfield 1,2, Jennifer C. Wakefield1,2, James D. Brenton 3,4,5, Khalid AbdulJabbar6,7, Antonella Savio8, Susan Freeman9,
Erika Pace1,2, Kerryn Lutchman-Singh10, Katherine M. Vroobel8, Yinyin Yuan6,7, Susana Banerjee11, Nuria Porta12,
Shan E. Ahmed Raza 6,7,13 and Nandita M. deSouza1,2
BACKGROUND: Diffusion-weighted magnetic resonance imaging (DW-MRI) potentially interrogates site-specific response to
neoadjuvant chemotherapy (NAC) in epithelial ovarian cancer (EOC).
METHODS: Participants with newly diagnosed EOC due for platinum-based chemotherapy and interval debulking surgery were
recruited prospectively in a multicentre study (n= 47 participants). Apparent diffusion coefficient (ADC) and solid tumour volume
(up to 10 lesions per participant) were obtained from DW-MRI before and after NAC (including double-baseline for repeatability
assessment in n= 19). Anatomically matched lesions were analysed after surgical excision (65 lesions obtained from 25
participants). A trained algorithm determined tumour cell fraction, percentage tumour and percentage necrosis on histology.
Whole-lesion post-NAC ADC and pre/post-NAC ADC changes were compared with histological metrics (residual tumour/necrosis)
for each tumour site (ovarian, omental, peritoneal, lymph node).
RESULTS: Tumour volume reduced at all sites after NAC. ADC increased between pre- and post-NAC measurements. Post-NAC ADC
correlated negatively with tumour cell fraction. Pre/post-NAC changes in ADC correlated positively with percentage necrosis.
Significant correlations were driven by peritoneal lesions.
CONCLUSIONS: Following NAC in EOC, the ADC (measured using DW-MRI) increases differentially at disease sites despite similar
tumour shrinkage, making its utility site-specific. After NAC, ADC correlates negatively with tumour cell fraction; change in ADC
correlates positively with percentage necrosis.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov NCT01505829.
British Journal of Cancer (2021) 124:1130–1137; https://doi.org/10.1038/s41416-020-01217-5
BACKGROUND
Epithelial ovarian cancer (EOC) of tubo-ovarian origin and primary
peritoneal cancer often present at an advanced stage when
multiple metastatic deposits in the pelvis and abdomen are
commonly seen.1 When primary debulking surgery is not feasible,
platinum-based neoadjuvant chemotherapy (NAC) is recom-
mended prior to interval debulking surgery (IDS) with the aim of
reducing the burden of disease and enabling complete macro-
scopic (R0) resection, as this is strongly linked to favourable
prognosis.2,3 However, it is now recognised that lesions may show
a differential response4, which is related to the tissue site at which
the deposits occur5 and the local microenvironment which may
promote development of resistant metastatic clones.6 If it were
possible to identify lesions that are likely to be poorly responsive
to neoadjuvant chemotherapy, these lesions could be specifically
targeted at surgical resection.
Traditionally, response in EOC has been assessed with
unidimensional size measurements, which have been shown to
be robust across tumour types and observer assessments.7
Response evaluation criteria in solid tumours (RECIST) criteria8
are well-established and widely used including in ovarian cancer.9
It is increasingly recognised, however, that early response in
tumours, with induction of necrosis by cytotoxic agents, may
precede changes in tumour size and requires additional imaging
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markers for its recognition.10 The apparent diffusion coefficient
(ADC) derived from diffusion-weighted magnetic resonance
imaging (DW-MRI) has been linked to tumour cellularity, but its
relationship to the necrotic fraction within a responding tumour
only has limited supporting evidence in some tumour types.11,12
This is largely because estimation of necrosis on pathological
specimens is variable when driven by observer assessments. Also,
digital analysis of the extent of necrosis13 has not been widely
available. In this study, we aimed to measure the change in ADC
metrics in EOC treated with platinum-based chemotherapy in a
quality-assured/controlled multicentre trial,14 compare the
changes in ADC between anatomic disease sites and relate them
to histological measures of response (residual viable tumour and
necrosis) as assessed by digital pathology.
METHODS
Participants
Participants with newly diagnosed stage III or IV ovarian, fallopian
tube or primary peritoneal cancer were recruited prospectively in
a multicentre trial with multicentre research ethics committee
approval (recruited 2012–2016, ClinicalTrials.gov NCT01505829,
study protocol available online (Supplementary Table 1)14).
Participants were enrolled at four hospitals (National Health
Service, United Kingdom). All participants gave written informed
consent. Inclusion criteria were histology/cytology-confirmed
high-grade serous, endometrioid or clear cell histology, at least
one solid mass >2 cm in long axis on CT or MRI and scheduled for
platinum-based NAC with IDS after three or four cycles. Exclusion
criteria were abdomino-pelvic radiotherapy within six months of
screening, contra-indications to MRI, or receipt of an investiga-
tional compound or device within 30 days of starting treatment.
Study design
Participants underwent baseline (pre-NAC) MRI examinations before
starting chemotherapy. Two pre-NAC MRI examinations were
conducted up to 7 days apart if participants were able to tolerate
both examinations; only one pre-NAC examination was conducted if
participants were unable to tolerate the second pre-NAC examina-
tion. Post-NAC MRI examinations were conducted after three or four
cycles of chemotherapy within 8 days prior to IDS.
MRI protocol
Slice-matched, DW-MRI, T1-weighted, and T2-weighted imaging
standardised between centres (with allowances for intervendor
and scanner variations15) covered the abdomen and pelvis in
three stations (Supplementary Table 1). Regular quality assurance
tests throughout the study ensured measurement stability.
Image analysis
Images were analysed at the lead centre using in-house software
(Adept, The Institute of Cancer Research, London, UK). Inter-
mediate signal intensity masses on T2-weighted images with
restricted diffusion identified as tumour were categorised by site
(ovary, peritoneum, omentum, and enlarged lymph node by
RECIST criteria). For each examination, regions-of-interest (ROIs)
encompassing the whole solid lesion on all slices were drawn by
region growing on computed b= 1000 smm−2 images16 by JCW
(2 years’ experience with pelvic MRI) and checked by NMdS (20
years’ experience). Cystic areas were excluded by visual matching
with T2-weighted images. Up to five target and five nontarget
largest lesions per participant were analysed. Lesions were
selected on pre-NAC MRI examinations and the same lesions
were followed-up on post-NAC MRI examinations. ADCs were
estimated by mono-exponential fitting of signal intensity at b-
values 100, 500 and 900 smm−2. The median ADC, 25th and 75th
centile (ADCmedian, ADC25, ADC75, respectively) were estimated
from all fitted voxels in the ROIs for each lesion. The volume of
each solid lesion was obtained by multiplying the number of
voxels in the ROIs by voxel volume (range 0.013–0.016 cm3). For
each lesion, the change in solid tumour volume and ADC after
three or four cycles of NAC was expressed as percentage change
from pre-NAC measurements.
Image-guided surgical sampling
Anatomical localisation diagrams provided to participating sur-
geons with detailed annotations on radiologist-selected imaged
target lesion location enabled matching of lesions with those
identified at surgery. These matched lesions were marked with
sutures at excision to identify them to the pathologist.
Histopathology analysis
Formalin fixed tissue specimens were sectioned at three to four-
millimetre intervals, embedded in paraffin and 2–3-micron
sections mounted on glass slides. Haematoxylin and eosin (H&E)
stained sections were reviewed by two gynaecological-oncology
histopathologists in consensus (AS, KV, 15 and 3 years’ experience
respectively). From each selected lesion, after review of the entire
lesion, they chose a single index slide that most closely
represented the residual viable tumour and necrosis across the
whole lesion.
Whole H&E stained slides were digitised to a resolution of 0.26
µm per pixel (Hamamatsu NanoZoomer XR scanner, Hamamatsu,
Japan). An algorithm previously trained to 92.61% accuracy on a
lung model was used to identify tumour cells, differentiating them
from stromal, lymphocytes and other cells such as macrophages.17
The proportion of viable tumour cells to total cells in the sample
(tumour cell fraction) was recorded. Areas of viable tumour and
necrosis outlined by AS on 20 slides were used to train a modified
algorithm (MicroNet) to segment tumour and necrosis regions on
the whole study sample.18 Algorithm training was deemed
acceptable on achieving 90% validation accuracy. A pretrained
H&E tissue segmentation algorithm removed background noise
and artefacts.17 The ratios of segmented tumour or necrosis area
to the whole-slide segmented tissue area were recorded as %
residual tumour and %necrosis, respectively.
Statistical analysis
Statistical analysis (NP) used commercially available software
(Stata, v15.1, StataCorp, College Station, TX, USA) and GraphPad
Prism for Windows, (v8.3, GraphPad Software Inc., San Diego, CA,
USA). P values < .05 were considered statistically significant.
Median, lower and upper quartiles were used to summarise
imaging and histology parameters.
95% limits of agreement (LoA)19 were used to assess repeat-
ability of solid tumour volume and ADCmedian for each disease site
(ovary, omentum, peritoneum and lymph nodes).
Probability density functions for voxel-wise ADC estimates were
determined for pre-NAC and post-NAC measurements; the first
pre-NAC examination was used in those with two examinations
(commercially available software, ksdensity, Matlab, v2016a, The
MathWorks Inc, Natick, MA, USA). Analysis was done on a per
lesion basis rather than a cumulative voxel analysis to remove bias
towards larger volumes, and the sum of probability density
estimates calculated for each anatomic location.
The ADCmedian before neoadjuvant chemotherapy (pre-NAC)
between lesions that remained measurable after neoadjuvant
chemotherapy (post-NAC), and those that became nonmeasurable
were compared using linear mixed-effects regression models to
each pre-NAC parameter, including status of lesion (measurable/
nonmeasurable) as a fixed effect and per-participant random
intercept effects to account for clustering within participants. For
those lesions that remained measurable post-NAC, further linear
mixed models were used to compare percentage change between
pre- and post-NAC in solid lesion volume and ADCmedian across
disease sites (fixed effect), adjusting by baseline pre-NAC values
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and including per-participant random intercept. Models were
fitted to logarithm-transformed data when normality assumption
did not hold (checked graphically by histograms and boxplots and
tested by Shapiro–Wilks test). Pairwise comparisons between
disease sites are presented with adjusted differences and p-values
corrected for multiplicity by Bonferroni.
The relationships between (i) post-NAC preoperative ADCmedian
and tumour cell fraction; (ii) post-NAC preoperative ADCmedian and %
residual tumour; (iii) pre/post-NAC change in ADCmedian, ADC25 and
ADC75 and %necrosis were assessed using Spearman’s correlation.
RESULTS
Participants and lesions
Fifty-two participants were enrolled. All participants were newly
diagnosed and chemo naïve. Five participants were excluded,
leaving 47 participants (47 women, median age 61 years,
interquartile range (IQR) 57–70 years) with pre-NAC DW-MRI
(Supplementary Fig. 1 and Supplementary Table 2); the five
excluded participants consisted of four who were found not to
have met the inclusion criteria (two had low grade final histology,
one had a final diagnosis of metastatic breast cancer, one had
metal hip prostheses) and one who did not undergo any MRI
examinations (Supplementary Fig. 1). 47/47 participants had high-
grade serous subtype. 3/47 were treated with carboplatin
monotherapy, and 44/47 treated with carboplatin and paclitaxel;
5/47 also received bevacizumab (Supplementary Table 2). Two pre-
NAC MRI examinations were available in 19/47 participants for
repeatability assessment. 7/47 participants did not undergo post-
NAC MRI examinations, leaving 40/52 participants in the final
imaging analysis (Supplementary Fig. 1). Of 247 lesions at pre-NAC
(50 ovarian, 114 peritoneal, 47 omental and 36 lymph node
lesions), 139 lesions (40 ovarian, 50 peritoneal, 27 omental and 22
lymph nodes) remained measurable on the high b-value DW-MRI
images after three or four cycles of chemotherapy in these
participants (example shown in Fig. 1). Of the 40/52 participants
with pre- and post-NAC DW-MRI, 7/40 participants did not have
IDS, and a further 8/40 had no analysable lesions on pathology that
were matched to the imaging, leaving 25/40 participants with
matched lesions on imaging and pathology (Supplementary Fig. 1).
Tumour burden and site-specific response
Site-specific repeatability for solid tumour volume was assessed in
123 lesions (20 ovarian, 52 peritoneal, 23 omental, 28 lymph node)
from 19 participants. 95% LoA were −19.2 to 17.9 cm3 for solid
elements of ovary, −5.7 to 5.4 cm3 for peritoneum, −43.2 to 42.3
cm3 for omentum and −3.2 to 2.2 cm3 for lymph nodes
(Supplementary Table 3). Pre- and post-NAC DW-MRI was available
in 40 participants (Supplementary Fig. 1). The volume of solid
tumour that remained measurable in post-NAC preoperative DW-
MRI is presented in Table 1 for each lesion site for pre- and post-
NAC measurements. Median (lower and upper quartile) site-
specific tumour burden reduction was −86.2 (−91.1, −72.6)% for
solid elements of ovary, −80.1 (−87.6, −64.2)% for peritoneum,
−89.4 (−97.4, −64.2)% for omentum and −80.8 (−90.6, −70.4)%
for lymph nodes (Table 1). Adjusting by pre-NAC solid tumour
volume, there were no statistically significant differences between
lesion sites in volume reduction (linear mixed model, log-scale,
global p= 0.14). 28 of 40 ovarian, 35 of 50 peritoneal, 19 of 27
omental and 14 of 22 lymph node lesions reduced in volume
below the lower LoA.
ADC metrics and site-specific response
Site-specific 95% LoA for ADCmedian were −10 to 9 × 10
−5 mm2s−1
for solid elements of ovary, −13 to 16 × 10−5 mm2s−1 for
peritoneum, −17 to 17 × 10−5 mm2s−1 for omentum and −27 to
21 × 10−5 mm2s−1 for lymph nodes (Supplementary Table 3).
Within lesions that remained measurable post-NAC, the ADCmedian
is presented in Table 1, for each lesion site in pre- and post-NAC
measurements, as well as the percentage change between pre-
and post-NAC. Probability density functions for ADC estimates
from all lesions at each anatomic location showed a shift towards
higher ADC after NAC (Fig. 2). For the change in ADCmedian, after
adjusting by pre-NAC ADCmedian and accounting for within-
participant correlation, there were differences in ADCmedian
change between peritoneal lesions and lymph node lesions
a b c
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Fig. 1 Site-specific response of EOC to neoadjuvant chemotherapy. Images in a 62-year-old woman with stage 3 high-grade serous
epithelial ovarian cancer show differential response in primary and metastatic lesions: a axial T2-weighted magnetic resonance imaging (MRI)
at baseline (pre-NAC), b corresponding axial high-b-value diffusion-weighted MRI (b= 900smm−2), c apparent diffusion coefficient (ADC) map
and d–f matched sections of the same imaging series after three cycles of platinum-based chemotherapy (post-NAC preoperative). (Scalebar
on the ADC map is in units of 10−5 mm2 s−1.) Delineation of regions of interest (ROIs) is shown in b, e for the left ovarian lesion (blue ROI) and
peritoneal lesion (red ROI). The ovarian lesion remained measurable on MRI after three cycles of chemotherapy and was included in the
imaging-pathology comparison, but the peritoneal lesion was nonmeasurable on MRI after three cycles of chemotherapy. MRI magnetic
resonance imaging, NAC neoadjuvant chemotherapy, ADC apparent diffusion coefficient, ROI region of interest.
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Fig. 2 Probability density functions for ADC estimates in all lesions at each anatomic site (ovarian, omental and peritoneal lesions and
lymph nodes) at baseline (pre-NAC) and after three or four cycles of treatment (post-NAC preoperative). Probability density functions have
been normalised to aid comparison between pre- and post-treatment data. The same points and bandwidth were used for all lesions
(bandwidths were determined for each lesion separately and the median bandwidth from all lesions estimated and applied to each lesion).
ADC apparent diffusion coefficient, NAC neoadjuvant chemotherapy.
Table 1. Solid lesion volume and ADCmedian for each disease site showing changes with NAC in lesions that remained measurable after treatment.
Pre-NAC values of lesions that were non-measurable after NAC are given for comparison.
Measurable lesions presurgery (after NAC) Nonmeasurable lesions
presurgery (after NAC)
n Pre-NAC Post-NAC Change/% n Pre-NAC
Solid tumour volume/cm3 (median [Q1–Q3])
Ovary 40 40.0 [22.3 to 107.4] 4.8 [2.2 to 14.5] −86.2 [−91.1 to −72.6] 10 7.2 [2.8 to 25.2]
Peritoneum 50 14.7 [4.9 to 71.7] 2.0 [1.2 to 9.9] −80.1 [−87.6 to −64.2] 64 5.5 [2.5 to 16.0]
Omentum 27 161.2 [57.2 to 275.8] 12.7 [2.1 to 36.4] −89.4 [−97.4 to −64.2] 20 30.0 [3.5 to 86.6]
Lymph node 22 6.1 [3.3 to 14.2] 1.0 [0.7 to 3.0] −80.8 [−90.6 to −70.4] 14 4.1 [1.5 to 8.9]
ADCmedian/10
−5 mm2 s−1 (median [Q1–Q3])
Ovary 40 99 [88 to 112] 122 [108 to 139] 18.6 [7.7 to 36.2] 10 95 [86 to 102]
Peritoneum 50 101 [87 to 112] 118 [101 to 129] 11.4 [1.4 to 30.7] 64 100 [89 to 112]
Omentum 27 110 [95 to 120] 123 [106 to 131] 5.6 [−7.8 to 24.5] 20 109 [98 to 118]
Lymph node 22 102 [94 to 107] 141 [128 to 166] 38.1 [23.3 to 67.6] 14 106 [89 to 114]
The median value is shown, with lower (Q1) and upper (Q3) quartiles shown in brackets.
n number of lesions, NAC neoadjuvant chemotherapy, ADC apparent diffusion coefficient (where ADCmedian is defined as the median ADC of all fitted voxels in
a lesion).
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(adjusted difference, diff=−23.4%, p= 0.001), and between
omental lesions and lymph node lesions (diff=−28.7%, p <
0.001), but no differences between peritoneal and omental (diff=
+5.2%, p= 0.99) or ovarian lesions (diff=−7.5%, p= 0.51), nor
between ovarian and nodal lesions (diff=−16.0%, p= 0.06) or
ovarian and omental (diff= 12.7%, p= 0.07). 28 of 40 ovarian, 24
of 50 peritoneal, 8 of 27 omental and 17 of 22 lymph node lesions
increased in ADCmedian above the upper LoA. The pre-NAC
ADCmedian of lesions that became nonmeasurable on post-NAC
scans was not significantly different from those that remained
measurable (Table 1), for ovarian lesions (diff= 3.9 × 10−5
mm2s−1, p= 0.58), peritoneal (diff= 4.11 × 10−5 mm2s−1, p=
0.17), omental (diff= 3.9 × 10−5 mm2s−1, p= 0.37) and lymph
nodes (diff= 5.2 × 10−5 mm2s−1, p= 0.29).
Comparison of ADC metrics with histological measures of
response
In total, 99 sections (37 ovarian, 31 peritoneal, 24 omental, 7
lymph node) from 93 lesions in 25 participants were assessed on
digital pathology (Fig. 3). Tumour cell fraction, %residual tumour
and %necrosis median (lower quartile and upper quartile) were
50.6% (46.0% and 63.1%), 7.5% (2.2% and 19.2%) and 54.5%
(35.1% and 69.6%), respectively, for ovary, 43.6% (36.0% and
50.5%), 7.8% (1.8% and 28.1%) and 56.3% (22.2% and 79.2%) for
peritoneum, 41.9% (25.5% and 59.1%), 3.0% (1.2% and 17.7%) and
52.9% (36.9% and 63.6%) for omentum, and 27.9% (14.0% and
32.5%), 3.3% (1.4% and 4.7%) and 26.5% (20.4% and 74.3%) for
lymph nodes.
Of these 99 sections, matched pathology and post-NAC DW-MRI
was obtained in 69 sections (29 ovarian, 20 peritoneal, 14 omental,
6 lymph node) from 65 lesions obtained from 25 participants (two
large ovarian lesions were sampled in two separate areas, one
large peritoneal mass was sampled in three separate areas).
Table 2 shows Spearman correlation between the change in ADC
metrics and histological features. When all lesions were consid-
ered together, post-NAC ADCmedian showed negative correlation
with tumour cell fraction (r=−0.34, p= 0.005). When considered
by disease site, this held true for the peritoneum (r=−0.45, p=
0.05) only. The change in ADCmedian for all sites considered
together showed positive correlation with %necrosis (r= 0.39, p
a b c
Fig. 3 Deep learning tumour and necrosis segmentation from pathologist annotations. a Example of an H&E section from an omental
lesion from a 63-year-old woman with stage 3 high-grade serous epithelial ovarian cancer; b shows tumour regions (red) and regions outlined
as part of the necrosis (orange) delineated by a pathologist in the lower half of the section. The unannotated standard H&E stain is seen in the
top half of the section. The same section after deep learning segmentation of the whole section (c), showing tumour (green) and necrosis
(yellow) for comparison. The correlation between the deep learning segmentation and the ground-truth pathologist segmentation is high.
The scalebar in a shows 100 microns. H&E haematoxylin and eosin.
Table 2. Spearman correlation of preoperative (post-NAC) ADC metrics and their change from pre-NAC values with histological measures of residual
















r p r p r p r p r p
Ovary (n= 29)b −0.30 0.11 −0.25 0.20 0.30 0.12 0.23 0.22 0.34 0.08
Peritoneum (n= 20)c −0.45 0.05 −0.47 0.04* 0.68 0.001* 0.71 <0.001* 0.61 0.005*
Omentum (n= 14) 0.02 0.93 0.24 0.42 0.01 0.97 0.25 0.41 0.00 0.99
Lymph node (n= 6) −0.71 0.11 −1.00 <0.001* 0.09 0.87 0.00 0.99 0.10 0.87
All sites (n= 69 sections from 65 lesions) −0.34 0.005* −0.27 0.02* 0.39 0.001* 0.45 <0.001* 0.40 <0.001*
tumour cell fraction= percentage of viable tumour cells to total cells in sample, %residual tumour= percentage area of whole section represented by viable
tumour, %necrosis= percentage area of whole section represented by necrosis.
NAC neoadjuvant chemotherapy, n number of lesions, ADC apparent diffusion coefficient (ADCmedian, ADC25 and ADC75 are defined as the median, 25th centile,
and 75th centile of ADC estimates from all fitted voxels in a lesion, respectively),
*P < 0.05; for lymph nodes, the sample is too small and the significant result may be due to chance.
aIn 2 peritoneal, 1 omental and 2 lymph node lesions, ADC25 and ADC75 could not be estimated.
b2 lesions with >1 histology assessment.
c1 lesion with >1 histology assessment.
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= 0.001) for the peritoneum (r= 0.68, p= 0.001). Illustration (Fig. 4)
is restricted to statistically significant correlations.
DISCUSSION
This study shows that in EOC/fallopian tube/primary peritoneal
cancer lesions responding to NAC, there is a differential increase in
ADC by anatomic site of the lesion despite a similar volume
reduction of >80%. This study also confirms a site-specific
correlation between the ADC changes and histological metrics
(tumour cell fraction, percentage necrosis). Thus, post-NAC
preoperative ADCmedian measurement is a clinically useful method
of detecting the presence or absence of viable tumour for
peritoneal deposits, but not at other sites. This is useful in
assessing relapsed disease, which is predominantly peritoneal.
These multicentre findings also confirm pilot data where a
negative correlation between epithelial cell density and diffusivity
was demonstrated in 15 lesions excised at IDS in participants with
primary ovarian or peritoneal cancer,4 and in 24 participants with
prostate cancer.20 In orthotopic preclinical models of solid ovarian
tumours, the change in ADC following docetaxel also was shown
to correlate negatively with Ki67, CA125 and Bcl-2, all of which
predict residual tumour burden.21
Although negative correlation between cell density and
diffusivity is widely accepted,22,23 the literature is inconclusive
about the effect of stroma, fibrosis and inflammatory infiltrate
on ADC values indicating that they are influenced by a complex
interplay of biophysical processes.24,25 In a tissue comprised
primarily of fat, such as the omentum, the return of normal fatty
stroma interspersed with residual tumour may obscure a post-
treatment ADC rise. This phenomenon is well-described in adult
bone marrow.26 This underlines the important contribution of
the surrounding normal tissue to the ADC and is borne out by
the omental data in this study, where ADC increases in
responding lesions were lower than other sites. The differences
between ADC response between peritoneal deposits and lymph
nodes is of interest, as both are densely cellular tissues. It may
well be that swelling and inflammatory response in lymph nodes
causes a much greater ADC rise than in the fibrotic peritoneum,
where inflammation and oedema is less. This requires further
investigation. The study was not powered to assess the
relationship of site-specific ADC change with progression-free
survival (PFS) in these treatment-naïve patients, although we
have previously shown that an increase in ADC of peritoneal
lesions after one cycle of chemotherapy indicates improved PFS
in relapsed disease.14
Only six lymph node lesions were analysable for imaging-
pathology correlations, which limits imaging-pathology compar-
isons for lymph nodes alone, but we have included these for
completeness in reporting this study. ADC changes in lymph
nodes following chemotherapy have been reported in
lymphomas,27,28 where abnormal nodal architecture results in
variable increases in ADC; imaging-pathology studies have not
been conducted as surgery is not part of the patient management.
In other cancer types involving lymph nodes, treatment is usually
chemoradiotherapy, where radiotherapy influences ADC rises29,30
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Fig. 4 Site-specific correlations between imaging and histopathology metrics. Comparison between a preoperative ADCmedian and tumour
cell fraction, and b percentage change in ADCmedian and %necrosis, showing all lesions considered together and ovarian, omental, peritoneal
lesions and lymph nodes considered separately. r= Spearman correlation coefficient, ADC apparent diffusion coefficient (where ADCmedian is
defined as the median ADC of all fitted voxels in a lesion), tumour cell fraction= percentage of viable tumour cells to total cells in sample, %
residual tumour= percentage area of whole section represented by viable tumour, %necrosis= percentage area of whole section represented
by necrosis.
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due to early acute tissue injury and swelling,31 and cannot be
easily compared to our findings.
ADC increases post-treatment have been shown to correlate
with percentage necrosis in preclinical studies.21 A multicentre
clinical trial in lung cancer concluded that presurgical ADC or
change in ADC did not correlate with pathologist-assessed
necrosis of resection specimens but assessment was dependent
on a single pathologist reading.32 Clinical evidence relating ADC
change following chemotherapy to subsequent necrosis may be
confounded by pre-existing microscopic necrosis within the
tumour; ADC change has been linked to necrosis in tumour types
without much pre-existing necrosis, but not in others.33
Our study has several limitations. First, lesions that became
unmeasurable, and therefore showed the greatest response, did
not contribute to the ADC measurements. Second, lesions that
could not be matched between pre-IDS MRI and histology
samples were excluded, which reduced the sample size. Moreover,
matching between the imaging and histology was done on the
larger resectable lesions that were easily identified at surgery;
smaller lesions, which may represent a bigger response, were not
available for histological correlation, possibly introducing bias
towards more slowly responding lesions. The selection bias was
minimised by choosing up to ten lesions per participant on the
baseline MRI from different anatomical sites that were represen-
tative of the participant’s disease. Third, the direction of
pathological sectioning did not always exactly match the axial
imaging plane. We addressed this by selecting a histological slice
that most accurately represented the proportions of residual
tumour and necrosis within each lesion, but this depended on
detailed pathologist review, not 3D molds.34 To minimise error,
this was done by an experienced specialist gynaecological
pathologist at a national cancer centre. However, selection of a
single histological slide per lesion also represented a fourth
limitation. Although analysis of the entire lesion may be ideal, it
was impractical to digitise and analyse large numbers of sections
in each lesion. Also, the resource to do this was limited and could
not be accommodated.
In conclusion, in this relatively small study in EOC, the ADC
repeatability and extent of increase following treatment is
anatomic site dependent. The post-NAC preoperative ADC and
change in ADC is an indicator of residual viable tumour and
percentage of necrosis, respectively, primarily within peritoneal
deposits. When using ADC as a response indicator in EOC lesions,
therefore, consideration must be given to the ADC increase
compared with measurement repeatability and to the
anatomic site.
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